Hindawi Pain Research and Management Volume 2021, Article ID 8836427, 24 pages https://doi.org/10.1155/2021/8836427

Research Article

Is Dry Needling Effective When Combined with Other Therapies for Myofascial Trigger Points Associated with Neck Pain Symptoms? A Systematic Review and Meta-Analysis

César Fernández-De-Las-Peñas , Gustavo Plaza-Manzano , Albardo Formas , Gustavo Plaza-Manzano , Gu

Correspondence should be addressed to César Fernández-De-Las-Peñas; cesar.fernandez@urjc.es

Received 24 August 2020; Accepted 20 January 2021; Published 2 February 2021

Academic Editor: Manfred Harth

Copyright © 2021 César Fernández-De-Las-Peñas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To evaluate the effects of combining dry needling with other physical therapy interventions versus the application of the other interventions or dry needling alone applied over trigger points (TrPs) associated to neck pain. Databases and Data Treatment. Electronic databases were searched for randomized controlled trials where at least one group received dry needling combined with other interventions for TrPs associated with neck pain. Outcomes included pain intensity, pain-related disability, pressure pain thresholds, and cervical range of motion. The risk of bias (RoB) was assessed using the Cochrane risk of bias tool, methodological quality was assessed with PEDro score, and the quality of evidence was assessed by using the GRADE approach. Between-groups mean differences (MD) and standardized mean difference (SMD) were calculated. Results. Eight trials were included. Dry needling combined with other interventions reduced pain intensity at short-term (SMD –1.46, 95% CI –2.25 to –0.67) and midterm (SMD –0.38, 95% CI –0.74 to –0.03) but not immediately after or at long-term compared with the other interventions alone. A small effect on pain-related disability was observed at short-term (SMD –0.45, 95% CI –0.87 to –0.03) but not at midterm or long-term. The inclusion of dry needling was also effective for improving pressure pain thresholds only at short-term (MD 112.02 kPa, 95% CI 27.99 to 196.06). No significant effects on cervical range of motion or pain catastrophism were observed. Conclusion. Low-to-moderate evidence suggests a positive effect to the combination of dry needling with other interventions for improving pain intensity, pain-related disability, pressure pain thresholds, and cervical range of motion in people with neck pain associated with TrPs at short-term. No midterm or long-term effects were observed.

¹Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Universidad Rey Juan Carlos (URJC), Alcorcón, Madrid, Spain

²Cátedra Institucional en Docencia, Clínica e Investigación en Fisioterapia: Terapia Manual, Punción Seca y Ejercicio Terapéutico, Universidad Rey Juan Carlos, Alcorcón, Madrid, Spain

³Department of Radiology, Rehabilitation and Physiotherapy, Universidad Complutense de Madrid, Madrid, Spain

⁴Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain

⁵Performance and sport rehabilitation Laboratory, Faculty of sport sciences, University of Castilla-La Mancha, Toledo, Spain ⁶Clínica Dinamia Fisioterapia, Madrid, Spain

⁷Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, MA, USA

⁸Rehabilitación San Fernando, Madrid, Spain

1. Introduction

Neck pain is the fourth ranked condition in number of years lived with disability [1] and has a lifetime prevalence of 70% and a point prevalence of 20% in the general population [2]. Physical therapy is often considered the first treatment option for people with neck pain. Different therapeutic strategies, e.g., cervical spine mobilizations and manipulations [3], thoracic manipulations [4], therapeutic exercise [5], or education [6], have shown to be effective for the treatment of neck pain. However, evidence supporting the use of other therapies proposed for the management of neck pain, such as dry needling, is still limited [7].

It is important to note that clinicians do not usually treat patients with neck pain with just one isolated intervention, and multimodal approaches are generally advocated. In fact, clinical practice guidelines for physical therapy management of people with neck pain recommend a combination of manual therapy combined with exercise as a potential therapeutic strategy for this population [8, 9]. Some systematic reviews have shown that the combination of two interventions seems to be more effective than the application of each intervention alone [10, 11]; however, others did not [12]. There are few systematic reviews and meta-analyses supporting an effect of dry needling for the management of neck pain [7, 13]. These reviews included trials investigating the isolated application of dry needling for patients with neck pain. No meta-analysis investigating the effects of adding dry needling to other physical therapy interventions for the management of trigger points (TrPs) associated to neck pain exists.

Therefore, the current systematic review and metaanalysis compares the effects of combining dry needling with other physical therapy interventions vs. application of other physical therapy interventions or dry needling alone applied over TrPs associated with neck pain symptoms.

2. Methods

This systematic review and meta-analysis adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [14]. The international OPS Registry registration link is https://doi.org/10.17605/OSF. IO/4J8H5.

- 2.1. Systematic Literature Search. Electronic literature searches were conducted on MEDLINE, CINAHL, PubMed, PEDro, Cochrane Library, SCOPUS, and Web of Science databases from their inception to 20 July 2020. When databases allowed limits, searches were restricted to randomized clinical trials. We also screened the reference lists of the identified trials. Bibliographical database search strategies were conducted with the assistance of an experienced health science librarian.
- 2.1.1. Population. Adults with myofascial TrPs in the cervical muscles associated with neck pain symptoms of musculoskeletal origin older than 18 years of age.

- 2.1.2. Intervention. Any form of muscular dry needling combined with other physical therapy interventions. Acupuncture was excluded.
- 2.1.3. Comparators. Acceptable comparator was the other physical therapy intervention applied alone, the intervention combined with sham dry needling, or the application of just dry needling alone.
- 2.1.4. Outcomes. The primary outcome measure was pain intensity or pain-related disability. Secondary outcomes included pressure pain thresholds or cervical range of motion. The search strategy for each database is available in Supplementary Table 1.
- 2.2. Selection Criteria. The systematic review included randomized clinical trials where at least one group received any form of dry needling combined with another intervention in people with TrPs associated with neck pain. Due to the heterogeneity in the terminology, we included the following diagnostic terms in the current meta-analysis: neck pain, myofascial neck pain, myofascial pain syndrome, and whiplash-associated pain.

The eligible criteria included adult population (>18 years old) with at least at one active TrP associated with neck pain symptoms, one group receiving dry needling targeting TrPs combined with other physiotherapy interventions, an acceptable comparator with other interventions alone or combined with sham/placebo or dry needling alone, and the primary outcome of the trial should include pain intensity (e.g., as measured with a visual analogue scale or numerical pain rate scale) or pain-related disability (e.g., as assessed with a specific-disease questionnaire). Secondary outcomes included pain sensitivity (e.g., pressure pain thresholds) or cervical range of motion (e.g., assessed with a goniometer). We excluded clinical trials including pain associated with neurological disorders (e.g., poststroke pain), postoperative neck pain and studies not published as a journal article, retrospective designs, pilot studies, needling using a traditional Chinese medicine approach, or use of injection therapy (e.g., lidocaine injection).

2.3. Screening, Selection Process, and Data Extraction. Articles identified from the different databases were independently reviewed by two authors. First, the duplicates were removed. Second, title and abstract of the articles were screened for potential eligibility. Third, a full-text read of potentially eligible studies was conducted. Authors were required to achieve a consensus on the included trials. In case of discrepancy between both reviewers, a third author participated in the process to reach the consensus for including or not including the study.

Data from each trial including study design, sample size, population, interventions, outcomes, and follow-ups were extracted independently by 2 authors in a standardized form. Both authors had to achieve a consensus on each item on the

data-extraction form. If disagreement occurred, a third author participated in the determination.

2.4. Assessment of Methodological Quality and Risk of Bias. Risk of bias and methodological quality of the included trials were independently assessed by two authors using the Cochrane risk of bias (RoB) assessment tool [15] and the Physiotherapy Evidence Database (PEDro) scale [16], respectively.

The RoB tool includes the following items: selection bias (randomization sequence generation and allocation concealment), performance bias (blinding participants and blinding therapists), detection bias (blinding outcome assessor), attrition bias (incomplete outcome data), reporting bias (source of funding bias/selecting outcome reporting), and other bias (sample size) [15]. Each item was classified as low risk, high risk, or unclear according to the Cochrane collaboration's tool [15].

The PEDro score evaluates the quality of the trial by assessing the following items: random allocation, concealed allocation, baseline between-groups similarity, participants blinding, therapists blinding, assessors blinding, dropouts, intention-to-treat statistical analysis, between-groups statistical comparison, point measures, and variability data [16]. A trial was considered of high-quality when the PEDro score was ≥ 6 over 10 points.

2.5. Level of Evidence. To evaluate the quality of the evidence, we used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach [17]. The evidence level was classified as high, moderate, low, or very low based on the following items: presence of the study limitations (RoB), indirectness of evidence, inconsistency of results/unexplained heterogeneity, imprecision of results, and high probability of publication bias [18]. The level of evidence was classified as high quality when all items were negative, moderate quality when one item included serious risk, low quality when two items showed serious risk or one item showed very serious risk, or very low quality when three or more items have serious risk or two or more showed very serious risk. This process was also independently performed by two authors, with the participation of a third one if discrepancy occurred.

2.6. Data Synthesis and Analysis. The meta-analysis was conducted using the Review Manager statistical software (RevMan version 5.3). Data synthesis was presented by groups according to the inclusion of TrP dry needling with other interventions vs. the same intervention alone or vs. TrP dry needling alone and by the follow-up period as immediately after, at short-term, midterm, and long-term, if data were available.

We extracted the sample size, means, and standard deviations for each variable. When the trial reported only standard errors, they were converted to standard deviations. When necessary, the mean scores and standard deviations were estimated from graphs. Also, if the trial presented

nonparametric values (median and interquartile range), they were converted to means and standard deviations [19, 20].

The between-groups mean differences (MD) of the trials were converted to SMD, with their 95% confidence intervals (CI). A random-effects model was used to determine the overall effect size (SMD). An effect size (SMD) of 0.8 or greater was considered large, between 0.5 and 0.8 as moderate, and between 0.2 and 0.5 as small. In general, P values < 0.05 were considered statistically significant [21]. The calculation of the effect size on pain and related-disability were obtained immediate after (less than one week) just one session and at short-term (1–12 weeks), midterm (12–24 weeks), and long-term (>24 weeks).

Cervical range of motion was pooled for each movement, i.e., flexion, extension, lateral-flexion, and rotation. When the trial calculated the total range of motion or either side separately for lateral-flexion and rotation, the mean was used in the main analysis.

The heterogeneity of the studies was assessed using the I^2 statistic. The Cochrane group has established the following interpretation of the I^2 statistic: 0%–40% may not be relevant/important heterogeneity; 30%–60% suggests moderate heterogeneity, 50%–90% represents substantial heterogeneity, and 75–100% considerable heterogeneity [22].

3. Results

3.1. Study Selection. The electronic searches identified 557 potential studies for review. After removing duplicates, 324 studies remained. Three hundred fifteen (n=315) were excluded based on examination of their titles or abstracts, leaving 9 articles for full-text analysis [23–31]. One trial was excluded due to the objective of the study was to observe the effectiveness on postneedling soreness [23]. A total of 8 trials [24–31] were included in the systematic review and in the quantitative analysis (Figure 1).

3.2. Study Characteristics. The characteristics of the participants of the included studies are shown in Table 1. All studies targeted active TrPs (i.e., those which referred pain reproduced the patient's symptoms) with the needle, five (62.5%) targeted TrPs in the posterior neck muscles from a pragmatic viewpoint [25-27, 29, 31], two just the upper trapezius muscle [24, 30], and the last one the upper trapezius and levator scapulae [28]. Although all trials included one group receiving dry needling, two did not report the presence of local twitch responses during the needling intervention [26, 27]. All clinical trials specified that dry needling was applied by a physical therapist. The combination of the interventions was grouped since six trials compared the combination of dry needling with other interventions against the application of that intervention alone [26-31], and the remaining two compared the combination of dry needling with other interventions against dry needling alone [24, 25]. There was heterogeneity in the complementary interventions since three trials used best evidencebased physical therapy approaches [26, 28, 31], two trials included just stretching [29, 30], one just exercise [27], one




FIGURE 1: Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Flow diagram.

pain neuroscience education [25], and the last one the application of percutaneous electrical nerve stimulation [24] (Table 1). All trials included pain intensity as the primary outcome, whereas six (62.5%) also assessed pain-related disability. Secondary outcomes (pressure pain thresholds and cervical range of motion) were assessed in five trials. In addition, pain catastrophizing was also assessed in three trials [25, 27, 31]; therefore, pooling data were also conducted. Supplementary Table 2 summarizes the characteristics of dry needling interventions applied in each trial.

4. Methodological Quality

The methodological quality scores ranged from 6 to 9 (mean: 7.2; SD: 1.1) out of a maximum of 10 points; therefore, all studies were considered of high methodological quality (\geq 6 points). No trial was able to blind the therapists. The most frequent bias was blinding participants since only three trials were able to do [26–28]. Table 2 represents the details of the PEDro scale of each trial.

4.1. Risk of Bias. The details of the risk of bias assessment of the included trials are displayed in Figure 2. No trial was able to blind therapists, and all trials had an unclear bias in the item of blinding participants. In general, the risk of bias of the included trials in the current meta-analysis was low.

4.2. Dry Needling Combined with Other Therapies on Pain Intensity. Dry needling combined with other physical therapy interventions did not exhibit a significant effect (MD -0.55 points, 95% CI -1.64 to 0.55, P = 0.33, Z = 0.98,

n = 159) for reducing pain intensity immediately after one single treatment session when compared with other interventions or dry needling alone, although this analysis was based on just one trial each (Figure 3(a)).

At short-term follow-up, the meta-analysis found that dry needling combined with other interventions showed a significant large effect (MD -1.76 points, 95% CI -2.66 to -0.86; SMD -1.46, 95% CI -2.25 to -0.67, P = 0.001, Z = 3.83, N = 550, 6 trials) for reducing pain intensity as compared to the other interventions alone or dry needling alone but with considerable heterogeneity ($I^2 = 94\%$) between the studies (Figure 3(b)). The effect was positive in both comparisons, dry needling combined with other interventions vs. the other interventions alone (MD -1.84 points, 95% CI -2.83 to -0.85), and dry needling with other interventions vs. dry needling alone (MD -1.21 points, 95% CI -2.15 to -0.27).

The results revealed that dry needling combined with other interventions exhibited a significant small effect (MD -0.52 points, 95% CI -0.79 to -0.25; SMD -0.38, 95% CI -0.74 to -0.03, P = 0.002, Z = 3.72, n = 237) for decreasing pain intensity at midterm than the other interventions or dry needling alone and without heterogeneity ($I^2 = 0\%$) between the trials (Figure 3(c)). The effect was significant for dry needling combined with other interventions vs. the other interventions alone (MD -0.52 points, 95% CI -0.80 to -0.24) but not for dry needling combined with other therapy vs. dry needling alone (MD -0.53 points, 95% CI -1.78 to 0.25).

No significant effect on pain (MD -1.30 points, 95% CI -3.27 to 0.66; SMD -0.64, 95% CI -1.20 to -0.08, P = 0.19, Z = 1.30, n = 324) was observed at the long-term follow-up for the inclusion of dry needling with other interventions

TABLE 1: Characteristics of the sample of included studies.

Tough et al., 2010 [26] Whiplash-associated disorders G2: sham DN + standardized physical therapy G3: TrP-DN + passive stretching G3: TrP-DN + passive stretching G4	Study	Diagnosis	Group	Total (male/female)	Age (SD), y	Pain duration
Tough et al., 2010 [26] Whiplash-associated disorders G2: sham DN + standardized physical therapy C2: sham DN + standardized physical therapy C3: sham DN + standardized physical therapy C4: sham DN + standardized physical therapy C3: sham DN + standardized physical therapy C4: sham DN + standardized physical physical therapy C4: sham DN + standardized physical physical physical physical therapy C4: sham DN + standardized physical physica	DN plus other therapies v	s. other therapies alone				
Chronic whiplash-associated disorders Chronic whiplash-associated disorders Chronic whiplash-associated disorders G1: TrP-DN + exercise therapy 40 (10/30) 41.5 (11.1) 20.6 (18.4	Tough at al. 2010 [26]	Whiplash-associated		20 (9/11)	34.2 (10.8)	6.8 (4.3) wk.
Cerezo Tellez et al., 2016 Chronic mechanical neck pain G2: sham TrP-DN + passive stretching G2: passive stretching G3: TrP-DN + passive stretching G3: passive stretching passive passiv	Tough et al., 2010 [20]	disorders		21 (8/13)	36.9 (10.9)	7.3 (4.7) wk.
Cerezo Tellez et al., 2016 Chronic mechanical neck pain G2: snam TrP-DN + exercise therapy 40 (10/30) 41.7 (12.3) 15.9 (12.3)		Chronic whinlash	1 /	40 (16/24)	41.5 (11.1)	20.6 (18.0) mo.
Cerezo Tellez et al., 2016 Chronic mechanical neck pain G2: passive stretching G3: TrP-DN + manual therapy G3: sham TrP-DN + manual therapy G3: sham TrP-DN + manual therapy G3: sham TrP-DN + manual therapy G3: passive stretching G3: G3: passive stretch	Sterling et al., 2015 [27]			40 (10/30)	41.7 (12.3)	15.9 (12.8) mo.
Cerezo-Tellez et al., Neck pain in office workers G1: TrP-DN + passive stretching G2: passive stretching G2: passive stretching G3: TrP-DN + passive stretching G3: TrP-DN + passive stretching G3: TrP-DN + manual therapy G3: sham TrP-DN + manual therapy G3: guideline based physical therapy G3: passive stretching G3: TrP-DN + guideline based physical therapy G3: guideline based physical therapy G3: guideline based physical therapy G3: passive stretching G3: TrP-DN + guideline based physical therapy G3: guideline based physical physical therapy G3: guideline based physical therapy G3: guideline based physical physical therapy G3: guideline based physical physical therapy G3: TrP-DN + pain neck pain G3: TrP-DN + pain neck pain G3: TrP-DN + pain neuroscience education G3: TrP-DN + pain neuroscience education G3: TrP-DN + pain neuroscience education G4: TrP-DN G4: TrP-DN G4: TrP-DN + pain neuroscience education G4: TrP-DN + pain neuroscience G4: TrP-DN + pain neuros			-	64	48 (15.7)	>6 mo.
Cerezo-Tellez et al., Neck pain in omce workers G2: passive stretching G3: TrP-DN + manual therapy 47 (13/34) 34.1 (7.6) >3 m G2: sham TrP-DN + manual therapy 53 (24/29) 34.6 (8.9) >3 m G3: TrP-DN + guideline based physical therapy G3: guideline based physical therapy G4: guideline based physical therapy G5: guideline based physical therapy G6: guideline based physical physical therapy G6: guideline based physical physical physical therapy G6: guideline based physical phy	[29]	neck pain	G2: passive stretching	64	52 (16.6)	>6 mo.
G2: passive stretching 22 (3/19) 47 (16.2) NR Gallego-Sendarrubias et al., 2020 [28] Chronic mechanical et al., 2020 [28] Chronic neck pain G2: sham TrP-DN + manual therapy G2: sham TrP-DN + manual therapy G2: sham TrP-DN + guideline based physical therapy G2: guideline based physical therapy G2: guideline based physical therapy G3: guideline based physical g3: TrP-DN + guideline based physical g3: TrP-DN + gain G3: DN alone G3: DN alone G3: DN alone G3: DN alone G3: DN + PENS G3: G3: TrP-DN G4: 40.33 (11.94) G3: TrP-DN G3: TrP-DN F3: TrP-DN F4: 40.35 (7.97) 64:94 (62.57)	,		*	22 (5/17)	40.1 (13.1)	NR
Chronic mechanical et al., 2020 [28] Chronic mechanical neck pain G2: sham TrP-DN + manual therapy 53 (24/29) 34.6 (8.9) >3 mechanical neck pain G2: sham TrP-DN + manual therapy 53 (24/29) 34.6 (8.9) >3 mechanical physical therapy 58 (14/44) 39.3 (9.9) 36.1 (12.4 mechanical physical therapy 58 (18/40) 36.9 (11.5) 41.6 (14.5 mechanical physical therapy 58 (18/40) 36.9 (11.5) 41.6 (14.5 mechanical physical therapy 58 (18/40) 36.9 (11.5) 41.6 (14.5 mechanical physical therapy 58 (18/40) 36.9 (11.5) 41.6 (14.5 mechanical physical therapy 58 (18/40) 36.9 (11.5) 41.6 (14.5 mechanical physical physical physical physical physical therapy 58 (18/40) 36.9 (11.5) 41.6 (14.5 mechanical physical physi	2016 [30]	workers	G2: passive stretching	22 (3/19)	47 (16.2)	NR
et al., 2020 [28] neck pain G2: snam IFP-DN + manual therapy Stieven et al., 2020 [31] Chronic neck pain G1: TrP-DN + guideline based physical therapy G2: guideline based physical therapy G2: guideline based physical therapy G3: guideline based physical gased physical therapy G3: guideline based physical gased physical gased physical therapy G3: guideline based physical gased p	Callogo Sandarrubias	Chronic machanical		47 (13/34)	34.1 (7.6)	>3 mo.
Stieven et al., 2020 [31] Chronic neck pain Physical therapy G2: guideline based physical therapy S8 (14/44) S8 (18/40) S8 (C			53 (24/29)	34.6 (8.9)	>3 mo.
G2: guideline based physical therapy 58 (18/40) 36.9 (11.5) 41.6 (14.5)	Cr: 4 1 2020 [21]			58 (14/44)	39.3 (9.9)	36.1 (12.4) mo.
León-Hernández et al., 2016 [24] Chronic myofascial neck pain G1: DN alone G2: DN + PENS 31 (7/24) 23.32 (4.77) 16.03 (17.24) 20.03 (19.25) Valiente-Castrillo et al., 2020 [25] Chronic myofascial neck pain G2: TrP-DN + pain neuroscience education 20 (4/16) 40.35 (7.97) 64.94 (62.25)	Stieven et al., 2020 [31]	Chronic neck pain	G2: guideline based physical	58 (18/40)	36.9 (11.5)	41.6 (14.1) mo.
2016 [24] neck pain G2: DN + PENS 31 (9/22) 26.81 (9.63) 19.36 (19.22) Valiente-Castrillo et al., 2020 [25] Chronic myofascial neck pain G2: TrP-DN + pain neuroscience education 20 (4/16) 40.33 (11.94) 43.39 (56.22) Valiente-Castrillo et al., 2020 [25] Chronic myofascial neck pain G2: TrP-DN + pain neuroscience education 21 (2/19) 40.35 (7.97) 64.94 (62.22)						
G1: TrP-DN 20 (4/16) 40.33 (11.94) 43.39 (56 Valiente-Castrillo et al., Chronic myofascial 2020 [25] G2: TrP-DN + pain neuroscience education 21 (2/19) 40.35 (7.97) 64.94 (62.1)				` '	, ,	` '
Valiente-Castrillo et al., Chronic myofascial 2020 [25]	2016 [24]	neck pain	G2: DN + PENS	31 (9/22)	26.81 (9.63)	19.36 (19.23) mo.
2020 [25] neck pain G2: TrP-DN + pain 21 (2/19) 40.35 (7.97) 64.94 (62.5)	Valiente Castrillo et al	Chronic myofascial	G1: TrP-DN	20 (4/16)		43.39 (56.54) mo.
$(C_2, c_2, c_3) = c_2 c_3 (N/A)$ 10 (2/16) 42 25 (0.42) 56 20 (672)	,			21 (2/19)	40.35 (7.97)	64.94 (62.93) mo.
G3: usual care (N/A) 19 (3/16) 42.35 (9.43) 56.29 (6/.			G3: usual care (N/A)	19 (3/16)	42.35 (9.43)	56.29 (67.74) mo.

TrP, trigger point; DN, dry needling; SDN, superficial dry needling; PENS, percutaneous electrical nerve stimulation; G, group; Y, years; NR, not reported; mo., months; wk., weeks.

TABLE 2: Score of randomized clinical trials with the PEDro scale.

	1	2	3	4	5	6	7	8	9	10	Total
Tough et al., 2010 [26]	Y	Y	Y	Y	N	Y	N	Y	Y	Y	8/10
Sterling et al., 2015 [27]	Y	Y	Y	Y	N	Y	Y	Y	Y	Y	9/10
Cerezo-Tellez et al., 2016 [29]	Y	N	Y	N	N	Y	Y	N	Y	Y	6/10
Cerezo-Tellez et al., 2016 [30]	Y	N	Y	N	N	Y	Y	N	Y	Y	6/10
León-Hernández et al., 2016 [24]	Y	N	Y	N	N	Y	Y	Y	Y	Y	7/10
Gallego-Sendarrubias et al., 2020 [28]	Y	N	Y	Y	N	N	Y	N	Y	Y	6/10
Stieven et al., 2020 [31]	Y	Y	Y	N	N	Y	Y	Y	Y	Y	8/10
Valiente-Castrillo et al., 2020 [25]	Y	N	Y	N	N	Y	Y	Y	Y	Y	7/10

1, random allocation of participants; 2, concealed allocation; 3, similarity between groups at baseline; 4, participant blinding; 5, therapist blinding; 6, assessor blinding; 7, fewer than 15% dropouts; 8, intention-to-treat analysis; 9, between-group statistical comparisons; 10, point measures and variability data.

(Figure 3(d)). Furthermore, considerable heterogeneity between the trials was observed ($I^2 = 98\%$). Table 3 summarizes the main results and raw data of the included studies.

4.3. Dry Needling Combined with Other Therapies on Related-Disability. A significant effect on related-disability for the combination of dry needling with other interventions was observed at short-term (SMD -0.45, 95% CI -0.87 to -0.03, P = 0.5, Z = 2.09, n = 506, Figure 4(a)) but not at midterm (SMD -0.16, 95% CI -0.44 to 0.11, P = 0.25, Z = 1.14,

n = 237, Figure 4(b)) and long-term (SMD -0.32, 95% CI -0.97 to 0.29, P = 0.35, Z = 0.94, n = 324, Figure 4(c)). The heterogeneity between trials was considerable ($I^2 = 81\%$) at short-term, not relevant ($I^2 = 11\%$) at midterm, and considerable ($I^2 = 88\%$) at long-term.

At short-term, a significant effect on pain-related disability was found when compared the combined application of dry needling against dry needling alone (SMD -0.77, 95% CI -1.40 to -0.13), but this analysis was based on just one trial (Figure 4(a)). Table 3 details the main results and raw data of the included studies.




FIGURE 2: Plot of risk of bias of the included studies.

4.4. Dry Needling Combined with Other Therapies on Pressure Pain Thresholds. The meta-analysis found that dry needling in combination with other therapies did not exhibit a significant effect for increasing pressure pain thresholds immediately after (MD 89.93 kPa, 95% CI -25.97 to 205.64, P=0.13, Z=1.52, n=159, Figure 5(a)), at midterm (MD 32.10 kPa, 95% CI -21.68 to 85.88, P=0.24, Z=1.17, n=80, Figure 5(c)), and at long-term (MD 53.26 kPa, 95% CI -66.28 to 172.80, P=0.38, Z=0.87, n=208, Figure 5(d)).

At short-term, dry needling combined with other therapies exhibited a significant effect (MD 112.02 kPa, 95% CI 27.99 to 196.06, P = 0.009, Z = 2.61, n = 352) for increasing pressure pain threshold when compared with the other interventions alone, although with considerable heterogeneity ($I^2 = 92\%$) between the studies (Figure 5(b)).

4.5. Dry Needling Combined with Other Therapies on Cervical Range of Motion. Dry needling combined with other interventions did not show a significant effect immediately after the intervention on the cervical range of motion when compared with the other interventions alone: flexion (MD 3.33, 95% CI -0.28 to 6.97, n = 159, Z = 1.81, P = 0.08, Figure 6(a). 1); extension (MD 2.43, 95% CI -1.30 to 6.16, n = 159, Z = 1.28, P = 0.20, Figure 6(b). 1); rotation (MD -0.03, 95% CI -5.71 to 5.64, n = 159, Z = 0.01, P = 0.99, Figure 6(c). 1); and lateral-flexion (MD 2.13, 95% CI -1.14 to 5.41, n = 159, Z = 1.28, P = 0.20, Figure 6(d)). Similarly, no significant effects at long-term were either observed for flexion (MD 2.89, 95% CI -4.67 to 10.45, n = 208, Z = 0.75, P = 0.45, Figure 6(a). 3); extension (MD 1.67, 95% CI -7.94to 11.27, n = 208, Z = 0.34, P = 0.73, Figure 6(b). 3); and rotation (MD 4.25, 95% CI -3.78 to 12.26, n = 208, Z = 1.04,




FIGURE 3: Comparison (mean differences) between the effects of dry needling combined with other interventions against other interventions on pain intensity (a) immediately after, (b) at short-term, (c) at midterm, and (d) at long-term.

TABLE 3: Main results and raw data of the included studies.

Study	Outcome/Group	Baseline mean (SD)	Immediate, less than one week after a single session	session Short-term, 1-12 weeks, mean (SD)	Midterm, 12–24 weeks, mean	Long-term, >24 weeks,
Dun to a state of the state of	and the second s	Joseph			(35)	(GG) imaiii
of account communical with other interior	Pain (VAS, 0–10)	4.9 (1.6)	ı	1.71 (2.0) (6 wk)	ı	ı
	. 15	5.0 (1.6)	I	3.2 (2.8) (6wk)	I	I
- E	G2	18.6 (8.7)	1	8.4 (7.8) (6 wk)	1	ı
lougn et al., 2010 [26]				Disability (NDI)		
	5 6	20.5 (7.6)		11.9 (8.8) (6 wk)		I
				Pain (NPRS, (0-10)		
	G1	5.6 (2.2)	ı	3.2 (2.0) (6 wk)	3.2 (2.1) (12 wk)	2.8 (2.4) (54 wk)
	G2	5.4 (2.0)	I		3.5 (2.3) (12 wk)	3.3 (2.6) (54 wk)
	i	3		Disability (NDI, %)		
	5 S	42.9 (15.2)	I	32.2 (16.8) (6 wk)	30.8 (17.1) (12 wk)	27.3 (16.5) (54 wk)
Sterling et al., 2015 [27]	75	42.9 (15.1)	I	32.7 (10.6) (0 WK) Cervical flexion (*)	32.1 (10.0) (12 WK)	34.1 (16.4) (34 WK)
[[] [] [] [] [] [] [] [] [] [E	39.7 (16.1)	ı		41.7 (18.7) (12 wk)	42.5 (16.5) (54 wk)
	5 5	39.7 (14.9)		41.2 (19.1) (6 wk)	39.6 (16.5) (12 wk)	44.3 (17.0) (54 wk)
				Cervical extension (°)		
	G1	33.3 (13.2)	I	39.9 (13.3) (6 wk)	39.8 (13.6) (12 wk)	42.3 (14.1) (54 wk)
	G2	36.3 (16.3)	1	41.8 (15.8) (6 wk)	40.8 (16.1) (12 wk)	46.1 (17.6) (54 wk)
			R	Right cervical rotation (°)		
	G1	45.8 (17.6)	I		52.0 (19.5) (12 wk)	54.0 (19.2) (54 wk)
	G2	42.0 (22.5)	I	52.5 (17.4) (6 wk)	48.8 (17.9) (12 wk)	55.7 (17.7) (54 wk)
	Ċ	3		Left cervical rotation (°)		
	: : : :	43.6 (16.3)	ı	49.5 (17.2) (6 wk)	49.7 (20.3) (12 wk)	51.3 (18.4) (54 wk)
	75	46.3 (15.1)	-	48.8 (15.8) (6 WK) Cernical rotation (mean calculated)	46.4 (16.3) (12WK)	51.4 (18.6) (54 WK)
	E	44.7 (16.95)		50.55 (17.8) (6 wk)	50.85 (19.9) (12 wk)	52.65 (18.8) (54 wk)
Sterling et al., 2015 [27]	G2	44.15 (18.8)	ı	50.65 (16.6) (6 wk)	47.6 (17.1) (12 wk)	53.55 (18.15) (54 wk)
				PPT (kPa)		
	GI	153.8 (100.4)	1	191.8 (79.1) (6 wk)	213.2 (137.0) (12 wk)	193.9 (112.1) (54 wk)
	G2	174.7 (108.5)		199.4 (122.1) (6 wk)	181.1 (106.5) (12 wk)	200.2 (100.6) (54 wk)
	[5]	18.0 (11.3)		rain catastropnizing (FCS) 11 0 (9 5) (6 wk)	11.8 (11.0) (12.wk)	8 0 (10 8) (54 wk)
	; ;	30.4 (12.0)				(11111) (1111) (1111)
	75)	20.4 (15.8)	1	17.6 (13.6) (6 WK)	16.7 (12.3) (12WK)	12.6 (11.8) (54 WK)
	Ċ	3		Pain (VAS, 0–10)		
	5 8	5.1 (1.6)	I	0.29 (0.88) (2 wk)	I	1.02 (2) (24 wk)
	75	0.1 (1.4)		5.53 (1.0) (2 WK) PPT (kPa) right franczius	I	3.3 (2.10) (24 WK)
	G1	205.93 (68.64)		480.51 (172.64) (2 wk)	ı	429.52 (212.08) (24 wk)
	G2	196.13 (58.83)	I	292.23 (86.32) (2 wk)	I	304.98 (125.52) (24 wk)
Cerezo Tellez et al., 2016 [29]				PPT (kPa) left trapezius		
	5 E	205.93 (78.45)	ı	462.86 (160) (2 wk)	I	413.82 (224) (24 wk)
	75	(04.07) (20.40)	16	PPT (kPa) mean calculated	I	300.93 (00) (24 WK)
	G1	205.93 (73.54)	ı	471.68 (166.32) (2 wk)	I	421.67 (218.04)
	G2	201.03 (68.64)	ı	294.68 (83.16) (2 wk)	1	305.95 (106.76)
				Cervical rotation (°)		
	G1	53.9 (11.25)	I	61.95 (7.04) (2 wk)	I	62.8 (7.12) (24 wk)
	G2	53.3 (9.05)	ı	55.31 (5.84) (2 wk)	I	55.29 (4.76) (24 wk)
	5	21 55 (0 1)		Cervical lateral-flexion ()		30 3 (5 76) (34].)
	5 G	59.95 (6.75)		30.09 (0.30) (2 WK) 31 96 (4.16) (2 Wk)		30.3 (6./6) (24 wk) 32 41 (5.72) (24 wk)
Cerezo Tellez et al., 2016 [29]	3		Ce	Cervical flexion-extension (*)		(**** ***) (******)
	G1	49.9 (9.45)	I	58.45 (6.56) (2 wk)	I	59.55 (7.2) (24 wk)
	G2	51 (8.3)	I		I	53.49 (9.08) (24 wk)
	[5]	30 5 (16)		Disability (NDI) 13.2 (16.48) (2 mb)		(4w bC) (31 81) C1
	5 6	(01) (.00	I	15.2 (10:46) (2 WK)	I	12 (10:10) (24 WK)
	G2	31 (12)	1	24.53 (14.16) (2 wk)	1	22.57 (14.72) (24 wk)

Table 3: Continued.

			, , , , , , , , , , , , , , , , , , , ,				
Study	Outcome/Group	Baseline mean (SD)	Immediate, less than one week after a single session		Short-term, 1-12 weeks, mean (SD)	Midterm, 12–24 weeks, mean (SD)	Long-term, >24 weeks, mean (SD)
				Pain (VAS, 0-10) ⁺	;		
	GI	5.8 (0.79)	I	Ö	0.10 (0.23) (2 wk)	I	I
	75	5.0 (1.34)	ı	3.	3.35 (0.95) (2 wk)	ı	I
	5	186 32 (68 64)	1		421 68 (147 09) (2 wk)	1	ı
	5	186.32 (68.64)	I	274	274.58 (137.29) (2 wk)	I	I
				Cervical flexion-extension (")			
Cerezo-Tellez et al 2016 [30]	Gl	47.55 (12.2)	Ι	53	59.8 (6.95) (2 wk)	ı	ı
C1000-1010 ct at; 2010 [50]	G2	52.2 (7.5)	ı		50.35 (11.35) (2 wk)	ı	I
	Ċ	(65)		Cervical rotation (")	(1 0) (0 0)		
	5 6	56.6 (13)	I	0 (66.8 (2.8) (2 wk)	I	I
	75	55.4 (11.9)	I	61 (Comingal Internal flaviors (C)	60.8 (2.65) (2 wk)	I	I
	GI	32.95 (10.65)	I		43.45 (7.8) (2 wk)	I	I
	: E	36.8 (10.5)	1	i	33 55 (9.2) (2 wk)	1	ı
	3	(6:01) 0:00			(NH Z) (Z:C) CC:C		
	5	(0.40)		Pain (NPRS, 0-10)	17 (0 01) (4	(Fr. C1) (52 0) 60 C	(J. 100) (NE 0) 200
	5 E	6.31 (0.72)		7	2.1/ (0.81) (4wk) 3.37 (1.22) (4 wk)	2.98 (U.63) (12 WK) 3.52 (0.95) (12 Wk)	3.26 (0.74) (24 WK) 3.60 (0.56) (24 WF)
	3	0.10 (1.07)	I	Disability (NDI. %)	.37 (1.22) (* Wh.)	3:32 (0:33) (12 WK)	3.00 (0.30) (24 WK)
[10] 0000 [10]	GI	26.52 (9.72)	II		22.94 (8.891) (4 wk)	23.08 (11.1) (12 wk)	24.99 (9.04) (24 wk)
Stieven et al., 2020 [31]	G2	27.13 (6.42)	ı	20	20.94 (10.4) (4 wk)	23.66 (8.91) (12 wk)	22.86 (7.28) (24 wk)
				Pain catastrophizing (PCS)			,
	Gl	23.67 (9.51)	ı	22	22.17 (6.04) (4 wk)	19.07 (7.89) (12 wk)	19.18 (6.47) (24 wk)
	G2	20.97 (8.56)	ı	21	21.08 (8.83) (4 wk)	21.26 (9.41) (12 wk)	18.94 (8.06) (24 wk)
			Pa	Pain (VAS, 0-10)			
	G	6.66 (1.4)	3.19 (1.6)		1.77 (1.4) (4 wk)	I	I
	G2	6.17 (1.6)	4.15 (1.9)		3.34 (1.2) (4 wk)	1	I
				PPT (kPa)			
	GI	171.61 (39.22)	303.02 (78.45)	355	355.97 (98.06) (4 wk)	ı	1
	G2	184.36 (49.033)	253.01 (78.45)		219.66 (68.64) (4wk)	I	I
	į			Disability (NDI)			
	5 6	28.95 (10.2)	76.81 (12.1)	4 ,	4.61 (6.2) (4 wk)	I	I
	75	23.69 (9.8)	/3.13 (10.5)	Cervical flevion (*)	11.52 (7.3) (4 wk)	I	I
Callace Sandamishing at al 2020 [28]	5	67.80 (13.5)	(621) (120)		78 38 (0 5) (4].)		
Camego-Schuaniuonas et an, 2020 [20]	; E	69.25 (11.1)	61 92 (11.5)		70.58 (9.4) (4 wk)		
	3			Cervical extension (")	(2007) (2007)		
	G1	52.32 (14.6)	82.60 (14.5)		69.09 (11.3) (4 wk)	ı	1
	G2	55.68 (11.5)	79.11 (13.2)	62	62.40 (10.4) (4 wk)	I	1
				Right rotation (*)			
	:5 :	74.28 (18.1)	81.45 (13.7)	òo i	87.55 (8.1) (4 wk)	ı	I
	G 2	74.60 (15.3)	79.13 (11.5)	78	78.79 (10.9) (4 wk)	ı	I
	<u>.</u>	(2.71) 92.17	82.02 (14.1)		87.19 (8.4) (4 wk)	I	I
	G2	73.81 (11.8)	79.12 (12.35)	78	78.89 (10.1) (4 wk)		
			Cervical rota	Cervical rotation (°) (mean calculated)			
	GI	73.03 (17.9)	59.60 (11.9)	87	87.37 (8.25) (4 wk)	I	I
	G2	74.2 (13.55)	56.28 (11.9)		78.84 (10.5) (4 wk)	I	I
	Ċ		Kight cer	Kight cervical lateral flexion ()			
	5 6	47.72 (14.3)	62.51 (10.5)	39	68.45 (12.5) (4 wk)	ı	I
Gallego-Sendarrubias et al., 2020 [28]	75	49.04 (15.1)	39.87 (10.0)) Teft cervical lateral flexion (*)	56.25 (15.0) (4 WK)	I	I
	GI	53.64 (10.8)	61.05 (11.2)		70.11 (10.8) (4 wk)	I	ı
	G2	55.43 (11.0)	58.07 (11.25)		59.77 (9.9) (4 wk)	I	I
	5	(22 (1) 0) (2	Cervical latera	Cervical lateral flexion (mean calculated)	(44)		
	5	50.08 (12.55)	I	60	.28 (11.65) (4 WK)	I	I
	G2	52.23 (12.05)	I	58	58.01 (11.45) (4 wk)	I	I

TABLE 3: Continued.

Study	Outcome/Group	Baseline mean (SD)	Immediate, less than one week after a single session	Short-term, 1-12 weeks, mean (SD)	Midterm, 12–24 weeks, mean (SD)	Long-term, >24 weeks, mean (SD)
Dry needling combined with other interventions vs. dry needling alone	ions vs. dry needling alone		O O O O O O O O O O O O O O O O O O O	7010		
	G1	5.00 (4.00–6.00)			I	I
	G2	5.00 (3.50–6.00)	2.00 (1.00–5.00) Disability (NDI)+	- till	I	I
	G1	9.50 (8.00-13.00)		-	1	ı
Tokn Homninger of al 2016 [24]	G2	11.00 (7.00–14.50)	6.00 (4.00–14.00)		I	I
Leon-Fremandez et al., 2016 [24]	61	52.05 (12.24)	Cervical Hexion () 53.76 (12.07)	exion()	I	I
	G2	52.42 (11.72)	51.07 (12.21)	ı	ı	I
			Cervical extension (°)	tension (°)		
	G1	58.62 (11.80)	62.98 (10.90)	I	I	1
	G2	58.11 (12.44)	60.26 (13.73)	I	I	I
			Cervical left lateral flexion (*)	eral flexion (*)		
	G1	38.16 (9.36)	41.80 (9.63)	1	I	1
	G2	39.05 (8.01)	39.77 (9.18)	I	I	1
			Cervical right lateral flexion (*)	teral flexion (°)		
	G1	37.55 (9.11)	40.75 (9.91)	I	ı	I
	G2	38.77 (10.46)	40.59 (9.67)	I	I	I
			Cervical lateral flexion (mean calculated)	n (mean calculated)		
	G1	37.85 (9.23)	41.27 (9.77)	1	ı	1
	G2	38.91 (9.23)	40.18 (9.42)	ı	ı	I
León-Hernández et al., 2016 [24]			Cervical left rotation (°)	rotation (°)		
	G1	59.31 (13.72)	59.59 (11.98)	ı	ı	I
	G2	61.40 (12.82)	64.33 (8.58)	ı	ı	I
			Cervical right rotation (*)	: rotation (*)		
	G1	60.50 (10.73)	61.18 (10.9)	I	I	I
	G2	60.36 (10.24)	62.22 (7.42)	I	I	1
			Cervical rotation (mean calculated)	mean calculated)		
	G1	59.90 (12.22)	60.38 (11.44)	ı	ı	I
	G2	60.88 (11.53)	63.27 (8)	I	I	I
			Pain (VAS, 0–10)			
	G1	5.79 (1.89)	ı	2.38 (1.85) (4 wk)	3.00 (1.73) (12 wk)	1
	G2	5.52 (1.80)	I	1.17 (1.12) (4 wk)	2.47 (2.31) (12 wk)	-
	G3 (N/A)	5.26 (1.46)	ı	3.85 (2.38) (4 wk)	3.91 (2.50) (12 wk)	1
			Disability (NDI)			
Englose to the Heat Or the Heat	G1	17.45 (4.94)	I	12.00 (5.68) (4 wk)	11.0 (6.06) (12 wk)	I
vaneme-Castrino et al, 2020 [25]	G2 (N/A)	15.80 (4.62)	1 1	7.19 (6.56) (4 wk) 13.21 (7.26) (4 w.b.)	7.57 (5.53) (12 WK) 13 78 (8 78) (12 w.b.)	1 1
	(VIIVI) CD	10.70 (5.52)	Pain catastronhizing (PCS)		(NW ZI) (0::0) 0::CI	l
	G1	16.95 (11.39)	donomo um i	12.10 (11.01) (4 wk)	11.75 (10.48) (12 wk)	I
	G2	16.55 (12.36)	I	7.33 (7.90) (4 wk)	6.61 (7.86) (12 wk)	ı
	G3 (N/A)	19.41 (11.37)	II	12.70 (10.95) (4 wk)	14.70 (10.26) (12 wk)	ı

⁺Data are expressed as median and interquartile range. They were converted to mean and standard deviation in the forest plots.




FIGURE 4: Comparison (standardized mean differences) between the effects of dry needling combined with other interventions against other interventions on pain-related disability (a) at short-term, (b) at midterm, and (c) at long-term.

P = 0.30, Figure 6(c). 3) for the combination of dry needling and other interventions. A significant effect at long-term was seen for lateral-flexion (MD 5.89, 95% CI 3.72 to 8.06, n = 128, Z = 5.32, P < 0.001, Figure 6(c). 3), although this analysis was based on just one study.

The meta-analysis observed a significant small short-term effect of dry needling combined with other interventions on the cervical range of motion: flexion (MD 6.01, 95% CI 2.86 to 9.16, n = 352, Z = 3.74, P < 0.001, Figure 6(a). 2); extension (MD 5.36, 95% CI 2.00 to 8.72, n = 352, Z = 3.13, P = 0.002, Figure 6(b). 2); rotation (MD 6.34, 95% CI 4.661 to 8.03, n = 352; Z = 7.38, P < 0.001, Figure 6(c). 2); lateral-flexion (MD 8.55, 95% CI 5.01 to 12.10, n = 272, Z = 4.73,

P < 0.001, Figure 6(d). 2). All analyses had moderate heterogeneity. Table 3 summarizes main results and raw data of the included studies.

4.6. Dry Needling Combined with Other Therapies on Pain Catastrophizing. The combination of dry needling with other therapies exhibits a significant small effect on pain catastrophism at midterm (MD -1.71, 95% CI -6.36 to 2.94; SMD -0.36, 95% CI -0.61 to -0.10, n = 237; Z = 2.69; P = 0.007, Figure 7(b)) but not at short-term (MD -3.01, 95% CI -8.33 to 2.30, n = 237; Z = 1.11; P = 0.27, Figure 7(a)) and long-term (MD -3.34, 95% CI -5.77 to -0.91; n = 196; Z = 0.72; P = 0.47, Figure 7(c)).




FIGURE 5: Comparison (mean differences) between the effects of dry needling combined with other interventions against other interventions on pressure pain thresholds (a) immediately after, (b) at short-term, (c) at midterm, and (d) at long-term.

4.7. Quality of Evidence (GRADE). Table 4 displays the details of GRADE assessment showing RoB, inconsistency of the results, indirectness of evidence, imprecision of results, and high probability of publication bias. The serious/very serious inconsistency of the results (heterogeneity) and the serious/very serious impression downgraded the evidence level of dry needling to low or very low.

4.8. Adverse Events. Seven trials (87.5%) reported information about adverse effects with all of them reporting just minor events and none reported any serious adverse effects. Postneedling soreness was the most common adverse event in all trials and resolved spontaneously in 24–48 h without further treatment (Supplementary Table 3).

A.1 Immediate

Ct 1 1	Dry need	lling pl	us other	Ot	her alo	ne	Weight	Mean difference	Mean difference
Study or subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, random, 95% CI	IV, random, 95% CI
Dry needing plus other therapies versus o	ther thera	pies alo	ne						
Gallego-Sendarrubias et al., 2020 Subtotal (95% CI) Heterogeneity: not applicable Test for overall effect: $Z = 1.61$ ($P = 0.11$)	76.81	12.1	47 47	73.13	10.5	53 53	64.8 64.8	3.68 [-0.79, 8.15] 3.68 [-0.79, 8.15]	
Dry plus other therapies versus DN alone León-Hernández et al., 2016 Subtotal (95% CI) Heterogeneity: not applicable Test for overall effect: $Z=0.85$ ($P=0.39$)	53.76	12.07	29 29	51.07	12.21	30 30	34.2 34.2	2.69 [-3.51, 8.89] 2.69 [-3.51, 8.89]	
Total (95% CI) Heterogeneity: $\tan^2 = 0.00$; $\cosh^2 = 0.06$, df Test for overall effect: $Z = 0.98$ ($P = 0.33$) Test for subgroup differences: $\cosh^2 = 0.06$,	`					83	100.0	3.34 [-0.28, 6.97]	-10 -5 0 5 10 (Other alone) (DN plus otherl)

A.2 Short-term

Ct., d., a., a., b.,	Dry need	iling pl	us other	Ot	her alo	ne	Weight	Mean difference	Mean difference
Study or subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, random, 95% CI	IV, random, 95% CI
Dry needing plus other therapies versu	s other thera	pies alo	ne						
Cerezo-Tellez et al., 2016	58.45	6.56	64	52.89	5.84	64	39.4	5.56 [3.41, 7.71]	- -
Cerezo-Tellez et al., 2016 (b)	59.8	6.95	22	50.35	11.35	22	19.3	9.45 [3.89, 15.01]	
Gallego-Sendarrubias et al., 2020	78.38	9.5	47	70.58	9.4	53	28.9	7.80 [4.09, 11.51]	_
Sterling et al. 2015	39.2	15.8	40	41.2	19.1	40	12.5	-2.00 [-9.68, 5.68]	
Subtotal (95% CI)			173			258	100.0	6.01 [2.86, 9.16]	•
Heterogeneity: $tau^2 = 5.35$; $chi^2 = 16.71$	1, df = 3 (P = 0)	0.08), I	$^{2} = 55\%$						
Test for overall effect: $Z = 3.74$ ($P = 0.0$	002)								
Total (95% CI)			173			179	100.0	-1.76 [-2.66, -0.86]	•
Heterogeneity: $tau^2 = 5.35$; $chi^2 = 6.71$,	df = 3 (P = 0.	$08), I^2$	= 55%					-	
Test for overall effect: $Z = 3.74$ ($P = 0.0$	002)								-20 -10 0 10 20
Test for subgroup differences: not appl									(Other alone) (DN plus otherl)

A.3 Long-term

Cr. 1	Dry need	lling pl	us other	Ot	her alo	ne	Weight	Mean difference	Mean	difference	
Study or subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, random, 95% CI	IV, rande	om, 95% CI	
Dry needing plus other therapies v	ersus other thera	pies alo	ne								
Cerezo-Tellez et al., 2016	59.55	7.2	64	53.49	9.08	64	59.7	6.06 [3.22, 8.90]		I -	
Sterling et al. 2015	42.5	16.5	40	44.3	17	40	40.3	-1.80 [-9.14, 5.54]			
Subtotal (95% CI)			104			104	100.0	-2.89 [-4.67, 10.45]	-		
Heterogeneity: tau ² = 22.83; chi ² =	3.83, $df = 1$ ($P = 0$	0.05), I ²	=74%								
Test for overall effect: $Z = 0.75$ ($P = 0.75$)	= 0.45)										
Total (95% CI)			104			104	100.0	2.89 [-4.67, -10.45]	-		
Heterogeneity: tau ² = 22.83; chi ² =	3.83, $df = 1$ ($P = 0$	0.05), I ²	=74%						-	1	-
Test for overall effect: $Z = 0.75$ ($P =$	= 0.45)							-20	-10	0 10	20
Test for subgroup differences: not	applicable								(Other alone)	(DN plus othe	erl)

(a)

FIGURE 6: Continued.

B.1 Immediate

Cr. 1	Dry nee	dling p	lus other	. 0	ther alo	one	Weight	Mean difference		Mea	ın differei	ice	
Study or subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, random, 95% C]	IV, rai	ndom, 95	% CI	
Dry needing plus other therapies versus o	ther thera	pies alo	one										
Gallego-Sendarrubias et al., 2020	64.19	12	47	61.92	11.5	53	65.1	2.27 [-2.35, 6.89]			_	_	
Subtotal (95% CI)			47			53	65.1	2.27 [-2.35, 6.89]				-	
Heterogeneity: not applicable											-		
Test for overall effect: $Z = 0.96$ ($P = 0.34$)													
Dry plus other therapies versus DN alone													
León-Hernández et al., 2016	62.98	10.9	29	60.26	13.73	30	34.9	2.72 [-3.59, 9.03]			_		
Subtotal (95% CI)			29			30	34.9	2.72 [-3.59, 9.03]		-		_	
Heterogeneity: not applicable											-		
Test for overall effect: $Z = 0.84$ ($P = 0.40$)													
Total (95% CI)			76			83	100.0%	2.43 [-1.30, 6.16]				-	
Heterogeneity: $tau^2 = 0.00$; $chi^2 = 0.01$, df	= 1 (P = 0.	91), I ²	= 0%						_	-			
Test for overall effect: $Z = 1.28$ ($P = 0.20$)									-20	-10	0	10	20
Test for subgroup differences: $chi^2 = 0.01$,	df = 1 (P =	= 0.91)	$I^2 = 0\%$						(C	ther alone)	(I	ON plus of	herl)

B.2 Short-term

Ct 1 1	Dry nee	dling p	lus other	0	ther alc	one	Weight	Mean difference	Mean difference
Study or subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, random, 95% CI	IV, random, 95% CI
Dry needing plus other therapies versu	s other thera	pies alc	ne						
Cerezo-Tellez et al,. 2016	58.45	6.56	64	52.89	5.84	64	37.4	5.56 [3.41, 7.71]	- -
Cerezo-Tellez et al., 2016 (b)	59.8	6.95	22	50.35	11.35	22	20.0	9.45 [3.89, 15.01]	
Gallego-Sendarrubias et al., 2020	69.09	11.3	47	62.4	10.4	53	25.7	6.69 [2.41, 10.97]	
Sterling et al., 2015	39.9	13.3	40	41.8	15.8	40	17.0	-1.90 [-8.30, 4.50]	
Subtotal (95% CI)			173			179	100.0	5.36 [2.00, 8.72]	•
Heterogeneity: $tau^2 = 6.65$; $chi^2 = 7.37$,	df = 3 (P = 0)	06), I ²	= 59%						
Test for overall effect: $Z = 3.13$ ($P = 0.0$	002)								
Total (95% CI)			173			179	100.0%	5.36 [2.00, 8.72]	•
Heterogeneity: $tau^2 = 6.65$; $chi^2 = 7.37$,	df = 3 (P = 0)	06), I ²	= 59%					-	
Test for overall effect: $Z = 3.13$ ($P = 0.0$	02)								-20 -10 0 10 20
Test for subgroup differences: not appl	icable								(Other alone) (DN plus otherl)

B.3 Long-term

Study or subgroup	Dry nee	dling p	lus other	. 0	ther alo	one	Weight	Mean difference		Mea	n diffe	rence	
study or subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, random, 95% C	I	IV, ran	dom,	95% CI	
Dry needing plus other therapies versu	s other thera	pies alo	ne										
Cerezo-Tellez et al., 2016	59.55	7.2	64	53.49	9.08	64	55.5	6.06 [3.22, 8.90]				_	
Sterling et al., 2015	42.3	14.1	40	46.1	17.6	40	44.5	-3.80 [-19.79, 3.19]]		+		
Subtotal (95% CI)			104			104	100.0	1.67 [-7.94, 11.27]					
Heterogeneity: $tau^2 = 41.20$; $chi^2 = 6.56$	6, df = 1 (P = 0)	0.01), <i>1</i>	$^{2} = 85\%$										
Test for overall effect: $Z = 0.34$ ($P = 0.7$	3)												
Total (95% CI)			104			104	100.0	1.67 [-7.94, 11.27]					
Heterogeneity: $tau^2 = 41.20$; $chi^2 = 6.56$	6, df = 1 (P = 0)	0.01), <i>1</i>	$^{2} = 85\%$					-	+	+	-		-
Test for overall effect: $Z = 0.34$ ($P = 0.7$	3)							-	-20	-10	0	10	20
Test for subgroup differences: not appl	icable								(O	ther alone)		(DN plus oth	nerl)

(b)

FIGURE 6: Continued.

C.1 Immediate

0. 1	Dry nee	dling p	lus other	0	ther alo	one	Weight	Mean difference		Mea	an differ	ence	
Study or subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, random, 95% CI		IV, ra	ndom, 9	5% CI	
Dry needing plus other therapies versus o	ther thera	pies alo	one										
Gallego-Sendarrubias et al., 2020	62.02	14.1	47	79.12	12.35	53	49.3	2.90 [-2.35, 8.13]		-	_		_
Subtotal (95% CI)			47			53	49.3	2.90 [-2.35, 8.13]					_
Heterogeneity: not applicable													
Test for overall effect: $Z = 1.09$ ($P = 0.28$)													
Dry plus other therapies versus DN alone													
León-Hernández et al., 2016	60.38	11.44	29	63.27	8	30	50.7	-2.89 [-7.94, 2.16]	_		_	_	
Subtotal (95% CI)			29			30	50.7	-2.89 [-7.94, 2.16]	-			-	
Heterogeneity: not applicable													
Test for overall effect: $Z = 1.12$ ($P = 0.26$)													
Total (95% CI)			76			83	100.0	2.43 [-1.30, 6.16]					
Heterogeneity: $tau^2 = 9.89$; $chi^2 = 2.44$, df	= 1 (P = 0)	.12), I2	= 59%								\top	-	
Test for overall effect: $Z = 0.01$ ($P = 0.99$)	-								-10	-5	0	5	10
Test for subgroup differences: $chi^2 = 2.44$,	df = 1 (P = 1)	= 0.12)	$I^2 = 59.0$	0%						1		(DM -1	(1)
5 1	,	,							(O	ther alone)		(DN plus of	tner)

C.2 Short-term


Study or subgroup	Dry nee	Dry needling plus other		Ot	her alo	ne	Weight	Mean difference	Mean difference				
Study or subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, random, 95% CI		IV, ra	ndom, 95	% CI	
Dry needing plus other therapies versu	is other thera	pies alo	one										
Cerezo-Tellez et al., 2016	61.95	7.04	64	55.31	5.84	64	32.9	6.64 [4.40, 8.88]				_	_
Cerezo-Tellez et al., 2016 (b)	66.8	2.8	22	60.8	2.65	22	45.9	6.00 [4.39, 7.61]				-	
Gallego-Sendarrubias et al., 2020	67.37	8.25	47	78.84	10.5	53	16.5	8.53 [4.85, 12.21]					
Sterling et al., 2015	50.55	17.8	40	50.65	16.6	40	4.7	-0.10 [-7.64, 7.44]			_		
Subtotal (95% CI)			173			179	100.0	6.34 [4.66, 8.03]					•
Heterogeneity: $tau^2 = 0.93$; $chi^2 = 4.40$,	df = 3 (P = 0)	.22), I ²	= 32%									-	
Test for overall effect: $Z = 7.38$ ($P = 0.0$	00001)												
Total (95% CI)			173			179	100.0	6.34 [4.66, 8.03]					
Heterogeneity: $tau^2 = 0.93$; $chi^2 = 4.40$,	df = 3 (P = 0)	.22), <i>F</i>	$^{2} = 32\%$					_	-+-	-	-	-	-
Test for overall effect: $Z = 7.38$ ($P < 0.0$	00001)								-10	-5	0	5	10
Test for subgroup differences: not appl	icable								(O	ther alon	e) (DN	plus oth	ner)

C.3 Long-term

Cr. 1	Dry nee	Dry needling plus other			Other alone			Mean difference	Mean difference				
Study or subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, random, 95% CI		IV, rai	ndom,	95% CI	
Dry needing plus other therapies ve	rsus other thera	pies alc	one										
Cerezo-Tellez et al., 2016	62.8	7.12	64	53.29	4.76	64	61.3	7.51 (5.41, 8.61)				-	_
Sterling et al., 2015	52.65	18.8	40	53.55	18.15	40	38.7	-0.90 (-9.00, 7.20)			-		
Subtotal (95% CI)			104			104	100.0	4.25 (-3.78, 12.28)		_			
Heterogeneity: $tau^2 = 26.26$; $chi^2 = 3$.88, df = 1 (P =	0.05); I	$^{2} = 74\%$										
Test for overall effect: $Z = 1.04$ ($P =$	0.30)												
Total (95% CI)			104			104	100.0	4.25 (-3.78, 12.28)		_			
Heterogeneity: $tau^2 = 26.26$; $chi^2 = 3$.88, df = 1 (P =	0.05), <i>I</i>	$^{2} = 74\%$					_	-	+	-	-	-
Test for overall effect: $Z = 1.04$ ($P =$	0.30)								-10	-5	0	5	10
Test for subgroup differences: not ap	plicable								(Oth	er alone)		(DN plus	other)

(c)

FIGURE 6: Continued.



Ct. 1	Dry nee	dling p	lus othe	r Ot	her alc	ne	Weight	Mean difference		Mea	n diffe	rence	
Study or subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, random, 95% CI		IV, rar	ndom,	95% CI	
Dry needing plus other therapies versus o	ther thera	pies alo	one										
Cerezo-Tellez et al., 2016	38.3	6.76	64	32.41	5.72	64	100.0	5.89 [3.72, 8.06]					_
Subtotal (95% CI)			64			64	100.0	5.89 [3.72, 8.06]					-
Heterogeneity: not applicable												_	
Test for overall effect: $Z = 5.32$ ($P < 0.000$	01)												
Total (95% CI)			64			64	100.0	5.89 [3.72, 8.06]					-
Heterogeneity: not applicable								_	-	-	-	$\overline{}$	-
Test for overall effect: $Z = 5.32$ ($P < 0.000$	01)								-10	-5	0	5	10
Test for subgroup differences: not applica	ble								(Oth	er alone)		(DN plus	other)

139

100.0

6.34 [4.66, 8.03]

-10 -5 0 5

(Other alone)

(DN plus other)

FIGURE 6: Comparison (mean differences) between the effects of dry needling combined with other interventions against other interventions on cervical range of motion in flexion (a), extension (b), rotation (c), and lateral-flexion (d) motion (1) immediately after, (2) at short-term, and (3) at long-term.

5. Discussion

5.1. Trigger Point Dry Needling Combined with Other Therapies. The objective of this meta-analysis was to compare the effects of the application of dry needling combined with other interventions against an intervention alone or dry needling alone applied over cervical TrPs associated with neck pain symptoms. We found low-to-moderate evidence suggesting a positive effect of including dry needling into physical therapy treatment for improving pain intensity at short-term and midterm and for improving pain-related disability at short-term as compared with the physical therapy intervention alone. Additionally, adding dry needling to a physical therapy intervention was also effective at short-term but not midterm and long-term, for

Test for overall effect: Z = 4.73 (P < 0.00001)

Test for overall effect: Z = 4.73 (P < 0.00001)

Test for subgroup differences: not applicable

Heterogeneity: $tau^2 = 6.16$; $chi^2 = 5.41$, df = 3 (P = 0.07), $I^2 = 63\%$

Total (95% CI)

increasing pressure pain thresholds and cervical range of motion. A small effect on pain catastrophism at midterm was found. The RoB of the clinical trials included in this study was generally low, but the inconsistency (heterogeneity) and imprecision of the results downgraded the level of evidence (GRADE).

The current meta-analysis is the first one investigating the impact of dry needling combined other interventions versus another intervention alone on pain intensity, related-disability, pressure pain sensitivity, cervical range of motion, and pain catastrophism in patients with TrPs associated with neck pain symptoms. Liu et al. [7] investigated the effects of the isolated application of dry needling and found low evidence supporting its effects immediately after and at 4 weeks when compared with control or sham. We found low-




FIGURE 7: Comparison (mean differences) between the effects of dry needling combined with other interventions against other interventions on pain catastrophism (a) at short-term, (b) at midterm, and (c) at long-term.

quality evidence supporting a small positive effect of the inclusion of dry needling into a physical therapy treatment for improving pain intensity and pain-related disability when compared with the physical therapy treatment approach alone; however, the effects were observed mostly at short-term and at midterm only for pain intensity. The decrease on pain of -0.96 points (95% CI -1.61 to -0.31) at short-term and of -1.84 points (95% CI -2.83 to -0.85) at midterm did not reach the minimal clinically important difference (MCID) of 2.1 points described for people with mechanical neck pain [32], although changes at midterm were slightly superior to the general MCID of 1.4 points determined by Bijur et al. [33]. Nevertheless, we should recognize that the lower bound estimate of the confidence intervals did not surpass the MCID in either case, limiting

the clinical relevance of these results. It is possible that some patients with TrPs associated with neck pain symptoms exhibit more benefits to dry needling than others. Based on current evidence, it seems that including dry needling into a physical therapy treatment approach could have only small effects at short-term and midterm follow-up periods for the treatment of neck pain associated to TrPs (low-to-moderate evidence); however, more studies are clearly needed.

We also found that adding dry needling into a physical therapy intervention has a moderate effect (low evidence) at short-term for decreasing pressure pain sensitivity (by increasing the pressure pain thresholds) and small effects for increasing cervical range of motion. These results agree with current theories supporting a potential hypoalgesic effect of dry needling [34], although differences were only significant

Table 4: Level of evidence (GRADE) for dry needling on pain intensity, pressure pain sensitivity, and cervical range of motion in patients with neck pain.

Number of studies	Risk of bias	Inconsistency	Indirectness of evidence	Imprecision	Publication bias	Quality of evidence	MD or SMD (95% CI)
Effects of the inclusion Immediate follow-up			intensity				
Overall effect $(n=2)$	No	Serious $(I^2 = 54\%)$	No	Very serious	No	Very low	MD -0.55 (-1.64 to 0.55)
DN plus other therapy vs. others (n = 1)	No	No	No	Serious	No	Low	MD -0.96 (-1.61 to -0.31)*
DN plus other therapy vs. DN alone $(n = 1)$	No	No	No	Very serious	No	Low	MD 0.21 (-1.20 to 1.62)
Short-term follow-up	(1-12 week	s after intervention	on)				
Overall effect $(n=7)$	No	Very serious $(I^2 = 94\%)$	No	No	No	Low	MD -1.76 (-2.66 to -0.86)*
DN plus other therapy vs. other $(n=6)$	No	Very serious $(I^2 = 95\%)$	No	No	No	Low	MD -1.84 (-2.83 to -0.85)*
DN plus other therapy vs. DN alone $(n = 1)$	No	No	No	Very serious	No	Low	MD -1.21 (-2.15 to -0.27)*
Midterm follow-up (1	12-24 weeks	s after intervention	n)				
Overall effect $(n=3)$	No	No $(I^2 = 0\%)$	No	Serious	No	Moderate	MD -0.52 (-0.79 to -0.25)*
DN plus other therapy vs. others $(n=2)$	No	No $(I^2 = 0\%)$	No	Serious	No	Moderate	MD -0.52 (-0.80 to -0.24)*
DN plus other therapy vs. DN alone $(n = 1)$	No	No	No	Serious	No	Moderate	MD -0.53 (-1.78 to 0.72)
Long-term follow-up	(more than	24 weeks after in	itervention)				
Overall effect $(n=3)$	No	Very serious $(I^2 = 98\%)$	No	No	No	Low	MD -1.11 (-2.56 to 0.35)
DN plus other therapy vs. others $(n=3)$	No	Very serious $(I^2 = 98\%)$	No	No	No	Low	MD -1.11 (-2.56 to 0.35)
Effects of the inclusion Short-term follow-up							
Overall effect $(n = 6)$	No	Very serious $(I^2 = 81\%)$	No	No	No	Low	SMD -0.45 (-0.87 to -0.03)*
DN plus other therapy vs. others $(n=5)$	No	Very serious $(I^2 = 84\%)$	No	No	No	Low	SMD -0.39 (-0.87 to 0.08)
DN plus other therapy vs. DN alone $(n = 1)$	No	No	No	Serious	No	Moderate	SMD -0.77 (-1.40 to -0.13)*
Midterm follow-up (1	12–24 weeks	s after intervention	n)				
Overall effect $(n=3)$	No	No $(I^2 = 11\%)$	No	Very serious	No	Low	SMD -0.16 (-0.44 to 0.11)
DN plus other therapy vs. others $(n=2)$	No	No $(I^2 = 0\%)$	No	Very serious	No	Low	SMD -0.07 (-0.35 to 0.21)
DN plus other therapy vs. DN alone $(n = 1)$	No	No	No	Very serious	No	Low	SMD -0.59 (-1.22 to 0.04)
Long-term follow-up	(more than	24 weeks after in	itervention)				
Overall effect $(n=3)$	No No	Very serious $(I^2 = 88\%)$	No	No	No	Low	SMD -0.32 (-0.97 to 0.29)

Table 4: Continued.

Number of studies	Risk of bias	Inconsistency	Indirectness of evidence	Imprecision	Publication bias	Quality of evidence	MD or SMD (95% CI)
DN plus other therapy vs. others $(n=3)$	No	Very serious $(I^2 = 88\%)$	No	No	No	Low	SMD -0.32 (-0.97 to 0.29)
Effects of the inclusion of Immediate follow-up		0 1					
Overall effect $(n=3)$	No	Serious $(I^2 = 79\%)$	No	Serious	No	Low	MD 40.26 (-20.42 to 100.94)
DN plus other therapy vs. others $(n=1)$	No	No	No	Serious	No	Moderate	MD 50.01 (19.20 to 80.82)*
DN plus other therapy vs. DN alone $(n = 2)$	No	Very serious $(I^2 = 80\%)$	No	Very serious	No	Very low	MD 69.18 (-107.93 to 246.28)
Short-term follow-up Overall effect $(n = 4)$	(1–12 weel No	Very serious $(I^2 = 91\%)$	on) No	No	No	Low	MD 110.43 (26.71 to 194.15)*
DN plus other therapy vs. others (n=4)	No	Very serious $(I^2 = 91\%)$	No	No	No	Low	MD 110.43 (26.71 to 194.15)*
Midterm follow-up (1	2–24 weeks	s after intervention	n)	17			MD 22 10 (21 69
Overall effect $(n=1)$	No	No	No	Very serious	No	Low	MD 32.10 (-21.68 to 85.88)
DN plus other therapy vs. others $(n=1)$	No	No	No	Very serious	No	Low	MD 32.10 (-21.68 to 85.88)
Long-term follow-up	(more than	24 weeks after in	ntervention)				MD 50.00
Overall effect $(n=2)$	No	Very serious $(I^2 = 88\%)$	No	Very serious	No	Very low	MD 50.09 (-64.61 to 164.78)
DN plus other therapy vs. others (n = 2)	No	Very serious $(I^2 = 88\%)$	No	Very serious	No	Very low	MD 50.09 (-64.61 to 164.78)
Effects of the inclusion of				tion			
Immediate follow-up Overall effect $(n = 2)$	No	No $(I^2 = 0\%)$	No No	Very serious	No	Low	MD 3.34 (-0.28 to 6.97)
DN plus other therapy vs. others $(n=1)$	No	No	No	Very serious	No	Low	MD 3.68 (-0.79 to 8.15)
DN plus other therapy vs. DN alone $(n = 1)$	No	No	No	Very serious	No	Low	MD 2.69 (-3.51 to 8.89)
Short-term follow-up	(1-12 week		on				
Overall effect $(n=4)$	No	Serious $(I^2 = 55\%)$	No	No	No	Moderate	MD 6.01 (2.86 to 9.16)*
DN plus other therapy vs. others $(n = 4)$	No	Serious $(I^2 = 55\%)$	No	No	No	Moderate	MD 6.01 (2.86 to 9.16)*
Long-term follow-up	(more than		ntervention)				
Overall effect $(n=2)$	No	Serious $(I^2 = 74\%)$	No	Serious	No	Low	MD 2.89 (-4.67 to 10.45)
DN plus other therapy vs. others (n=2)	No	Serious $(I^2 = 74\%)$	No	Serious	No	Low	MD 2.89 (-4.67 to 10.45)

Table 4: Continued.

Number of studies	Risk of bias	Inconsistency	Indirectness of evidence	Imprecision	Publication bias	Quality of evidence	MD or SMD (95% CI)
Effects of the inclusion Immediate follow-up				notion			
Overall effect $(n=2)$	No	No $(I^2 = 0\%)$	No	Very serious	No	Low	MD 2.43 (-1.30 to 6.16)
DN plus other therapy vs. others $(n = 1)$	No	No	No	Very serious	No	Low	MD 2.27 (-2.35 to 6.89)
DN plus other therapy vs. DN alone $(n = 1)$	No	No	No	Very serious	No	Low	MD 2.72 (-3.59 to 9.03)
Short-term follow-up	(1 12 wool	ze after intervention	\n)				
Overall effect $(n=4)$	No	Serious $(I^2 = 59\%)$	No	No	No	Moderate	MD 5.36 (2.00 to 8.72)*
DN plus other therapy vs. others $(n = 4)$	No	Serious $(I^2 = 59\%)$	No	No	No	Moderate	MD 5.36 (2.00 to 8.72)*
Long-term follow-up	(more than	24 weeks after in	ntervention)				
Overall effect $(n=2)$	No	Very serious $(I^2 = 85\%)$	No	Serious	No	Very low	MD 1.67 (-7.94 to 11.27)
DN plus other therapy vs. others $(n=2)$	No	Very serious $(I^2 = 85\%)$	No	Serious	No	Very low	MD 1.67 (-7.94 to 11.27)
Effects of the inclusion	of dry need	lling on cervical re	otation range of m	otion			
Immediate follow-up							
Overall effect $(n=2)$	No	Serious $(I^2 = 59\%)$	No	Very serious	No	Very low	MD -0.03 (-5.71 to 5.64)
DN plus other therapy vs. others $(n = 1)$	No	No	No	Very serious	No	Low	MD 2.90 (-2.33 to 8.13)
DN plus other therapy vs. DN alone $(n = 1)$	No	No	No	Very serious	No	Low	MD -2.89 (-7.94 to 2.16)
Short-term follow-up	(1_12 week	s after intervention	n)				
Overall effect $(n=4)$	No No	No $(I^2 = 32\%)$	No	No	No	High	MD 6.34 (4.66 to 8.03)*
DN plus other therapy vs. others $(n=4)$	No	No $(I^2 = 32\%)$	No	No	No	High	MD 6.34 (4.66 to 8.03)*
Long-term follow-up	(more than	24 weeks after in	ntervention)				
Overall effect $(n=2)$	No	Serious $(I^2 = 74\%)$	No	Serious	No	Low	MD 4.25 (-3.78 to 12.28)
DN plus other therapy vs. others $(n = 2)$	No	Serious $(I^2 = 74\%)$	No	Serious	No	Low	MD 4.25 (-3.78 to 12.28)
Effects of the inclusion	of dry need	lling on carvical la	iteral flevion rango	of motion			
Immediate follow-up				or motion			
Overall effect $(n=2)$	No	No $(I^2 = 0\%)$	No	Very serious	No	Low	MD 2.13 (-1.14 to 5.41)
DN plus other therapy vs. others $(n = 1)$	No	No	No	Very serious	No	Low	MD 2.98 (-1.43 to 7.39)
DN plus other therapy vs. DN	No	No	No	Very serious	No	Low	MD 1.09 (-1.14 to 5.41)
alone $(n=1)$	(1 12 1	G · · · · · · · · · · · · · · ·	\				
Short-term follow-up Overall effect (n = 3)	(1–12 weel No	after intervention Serious $(I^2 = 63\%)$	on) No	Serious	No	Low	MD 8.55 (5.01 to 12.10)*

Table 4: Continued.

Number of studies	Risk of bias	Inconsistency	Indirectness of evidence	Imprecision	Publication bias	Quality of evidence	MD or SMD (95% CI)
DN plus other therapy vs. others $(n=3)$	No	Serious $(I^2 = 63\%)$	No	Serious	No	Low	MD 8.55 (5.01 to 12.10)*
Long-term follow-up	(more than	24 weeks after in	ntervention)				
Overall effect $(n=1)$	No	No	No	Very serious	No	Low	MD 5.89 (3.72 to 8.06)*
DN plus other therapy vs. others $(n = 1)$	No	No	No	Very serious	No	Low	MD 5.89 (3.72 to 8.06)*
Effects of the inclusion of	of dry need	lling on pain catas	strophizing				
Short-term follow-up	(1-12 week	ks after intervention	on)				
Overall effect $(n=3)$	No	Serious $(I^2 = 76\%)$	No	Very serious	No	Very low	MD -3.01 (-8.33 to 2.30)
DN plus other therapy vs. others $(n = 2)$	No	Very serious $(I^2 = 85\%)$	No	Very serious	No	Very low	MD -2.44 (-9.95 to 5.07)
DN plus other therapy vs. DN alone $(n = 1)$	No	No	No	Very serious	No	Low	MD -4.77 (-10.66 to 1.12)
Midterm follow-up (1	2–24 weeks	s after intervention	n)				
Overall effect $(n=3)$	No	No $(I^2 = 0\%)$	No	Serious	No	Moderate	MD -3.34 (-5.77 to -0.91)*
DN plus other therapy vs. others $(n = 2)$	No	No $(I^2 = 0\%)$	No	Serious	No	Moderate	MD -2.94 (5.63 to -0.25)*
DN plus other therapy vs. DN alone $(n = 1)$	No	No	No	Very serious	No	Low	MD -5.14 (-10.83 to 0.55)
Long-term follow-up	(more than	24 weeks after in	ntervention)				
Overall effect $(n=2)$	No	Serious $(I^2 = 65\%)$	No	Very serious	No	Very low	MD -1.71 (-6.36 to 2.94)
DN plus other therapy vs. others $(n=2)$	No	Serious $(I^2 = 65\%)$	No	Very serious	No	Very low	MD -1.71 (-6.36 to 2.94)

*Statistically significant (P < 0.05). Risk of bias: No, most information is from results at low risk of bias; Serious, crucial limitation for one criterion or some limitations for multiple criteria, sufficient to lower confidence in the estimate of the effect; Very serious, crucial limitation for one or more criteria sufficient to substantially lower confidence in the estimate of the effect. Inconsistency: Serious, $I^2 > 40\%$; Very serious, $I^2 > 80\%$. Indirectness of evidence, no indirectness of evidence was found in any study. Imprecision (based on sample size): Serious, $I^2 > 40\%$; Very serious, $I^2 > 80\%$. Indirectness of evidence, no indirectness of evidence was found in any study. Imprecision (based on sample size): Serious, $I^2 > 40\%$; Very serious, $I^2 > 80\%$. Indirectness of evidence, no indirectness of evidence was found in any study. Imprecision (based on sample size): Serious, $I^2 > 40\%$; Very serious, $I^2 > 80\%$. Indirectness of evidence, no indirectness of evidence was found in any study. Imprecision (based on sample size): Serious, $I^2 > 40\%$; Very serious, $I^2 > 80\%$. Indirectness of evidence, no indirectness of evidence was found in any study. Imprecision (based on sample size): Serious, $I^2 > 40\%$; Very serious, $I^2 > 80\%$. Indirectness of evidence was found in any study. Imprecision (based on sample size): Serious, $I^2 > 40\%$; Very serious, $I^2 > 80\%$. Indirectness of evidence was found in any study. Imprecision (based on sample size): Serious, $I^2 > 40\%$; Very serious, $I^2 > 80\%$. Indirectness of evidence was found in any study. Imprecision (based on sample size): Serious, $I^2 > 40\%$; Very serious, $I^2 > 80\%$. Indirectness of evidence was found in any study. Imprecision (based on sample size): Serious, $I^2 > 40\%$; Very serious, $I^2 > 80\%$. Indirectness of evidence was found in any study. Imprecision (based on sample size): Serious, $I^2 > 40\%$; Very serious, $I^2 > 80\%$. Indirectness of evidence was found in any study.

for short-term. It is possible that this neurophysiological effect is short-lasting. On the contrary, the effects of adding dry needling on cervical range of motion were small and should not be considered as clinically relevant. These results may be related to the fact that most trials included in the current meta-analysis have shown positive effects on these outcomes, and the inclusion of another intervention does not lead to better results, which has been also found when combining manual therapy with exercise for the management of neck pain [12]. This can be also related to the fact that manual therapy approaches [35] and dry needling interventions [34] share common neurophysiological mechanisms, and they only potentiate their effects on a subgroup of patients. Future studies should investigate this.

5.2. Safety of Trigger Point Needling. Since dry needling is an invasive intervention, clinicians should monitor the presence of adverse events. Carlesso et al. [36] defined an adverse

event "as a sequela of medium-term duration with any symptom perceived as unacceptable to the patient and requiring further treatment." Adverse events can be categorized as minor, moderate, or major. Previous studies have found that most events occurring after application of dry needling, such as bleeding or postneedling soreness, can be categorized as minor adverse events [37, 38]. Most studies included in this meta-analysis monitored the presence of adverse events during the study and reported the presence of postneedling soreness as the most common adverse event, supporting that dry needling seems to be a potentially safe intervention. Nevertheless, major adverse events, e.g., pneumothorax, have been also reported in the literature when applied dry needling to the cervical and thoracic spine, although their rate is less than 0.1% (1 per 1,024 needling treatments) and depend on the anatomical location. In fact, case reports describing pneumothorax after dry needling treatment have applied the intervention over thoracic musculature [39, 40]. Although dry needling seems to be a safe intervention if properly applied, therapists need to be aware of the potential risks associated with its application on each body area where it is applied.

5.3. Strengths and Limitations. The results of the current meta-analysis should be generalized within the context of its potential strengths and limitations. The strengths include a comprehensive literature search, methodological rigor, exhaustive data extraction, rigorous statistical analysis, and the inclusion of randomized controlled trials of high methodological quality. Among the limitations, we recognized that dry needling was applied with different dosages, that is, sessions, frequency of application, and combined with a variety of interventions exhibiting different evidence (e.g., manual therapy, stretching, and exercise). Second, the heterogeneity and imprecision of the results of the trials was serious; therefore, current results should be taken with caution. Third, the number of trials in some comparisons was small (n=3) which limits the extrapolation of the results. It is possible that a greater number of high-quality clinical trials investigating midterm and long-term effects of dry needling combined with more detailed physical therapy interventions would lead to different results.

5.4. Clinical and Research Implications. Although this is the first meta-analysis investigating the effects of adding dry needling to other physical therapy interventions in patients with neck pain associated to myofascial TrPs, several questions remain to be elucidated. First, just few studies investigating long-term follow-up periods are available in the literature. Second, trials in this meta-analysis investigated different physiotherapy approaches in heterogeneous populations (traumatic vs. insidious onset). Third, since neck pain is characterized by motor control disturbances, the inclusion of dry needling could lead to changes in muscle strength outcomes in this population. A recent meta-analysis reported medium effect sizes for dry needling to enhance force production in individuals with neck pain (moderate evidence), although this analysis was just based on two studies [41]. In fact, these two studies were included in the current meta-analysis, but we did not pool data from strength outcomes due to the heterogeneous interventions applied in them. It is probable that the combination of dry needling would be not as effective as it can be with any physical therapy intervention. Proper understanding of the clinical presentation of each individual patient and the underlying mechanisms of each intervention could lead to better clinical outcomes.

6. Conclusion

The current meta-analysis found low-to-moderate evidence suggesting a positive effect of adding dry needling into a physical therapy approach for improving pain intensity at short-term and midterm and for improving pain-related disability at short-term as compared with the same intervention applied alone. Additionally, adding dry needling was effective at short-term for increasing pressure pain

thresholds and cervical range of motion and on pain catastrophism at midterm. Although the methodological quality of the included trials was high, the inconsistency (heterogeneity) and imprecision of the results downgraded the overall levels of evidence.

Data Availability

No data are publicly available since this is a systematic review and meta-analysis.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors' Contributions

CFdlP, GPM, MNS, JSI, GGC, and JLAB conducted literature review and did the statistical analysis. CFdlP, ILdUV, and JAC contributed to drafting the paper. All authors contributed to the study concept and design, contributed to interpretation of data, revised the text for intellectual content, and have read and approved the final version of the manuscript.

Supplementary Materials

Supplementary Table 1: database formulas during literature search; Supplementary Table 2: characteristics of the dry needling intervention of the included studies; Supplementary Table 3: adverse events described in the included studies. (Supplementary Materials)

References

- [1] T. Vos, A. A. Abajobir, K. H. Abate et al., "Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016," *Lancet*, vol. 390, pp. 1211–1259, 2017.
- [2] D. Hoy, L. March, A. Woolf et al., "The global burden of neck pain: estimates from the global burden of disease 2010 study," *Annals of the Rheumatic Diseases*, vol. 73, no. 7, pp. 1309– 1315, 2014.
- [3] A. Gross, P. Langevin, S. J. Burnie et al., "Manipulation and mobilisation for neck pain contrasted against an inactive control or another active treatment," *Cochrane Database Systematic Review*, vol. 9, 2015.
- [4] M. Masaracchio, K. Kirker, R. States, W. J. Hanney, X. Liu, and M. Kolber, "Thoracic spine manipulation for the management of mechanical neck pain: a systematic review and meta-analysis," *PLoS One*, vol. 14, pp. 1–28, 2019.
- [5] A. Gross, T. M. Kay, J. Paquin et al., "Exercises for mechanical neck disorders," *Cochrane Database Systematic Review*, vol. 8, 2015.
- [6] A. Gross, M. Forget, K. St George et al., "Patient education for neck pain," *Cochrane Database Systematic Review*, vol. 3, 2012.
- [7] L. Liu, Q.-M. Huang, Q.-G. Liu et al., "Effectiveness of dry needling for myofascial trigger points associated with neck and shoulder pain: a systematic review and meta-analysis,"

- Archives of Physical Medicine and Rehabilitation, vol. 96, no. 5, pp. 944-955, 2015.
- [8] J. D. Bier, W. G. M. Scholten-Peeters, J. B. Staal et al., "Clinical practice guideline for physical therapy assessment and treatment in patients with nonspecific neck pain," *Physical Therapy*, vol. 98, no. 3, pp. 162–171, 2018.
- [9] P. R. Blanpied, A. R. Gross, J. M. Elliott et al., "Neck pain: revision 2017," *Journal of Orthopaedic & Sports Physical Therapy*, vol. 47, no. 7, pp. A1–A83, 2017.
- [10] A. Romeo, C. Vanti, V. Boldrini et al., "Cervical radiculopathy: effectiveness of adding traction to physical therapy-A systematic review and meta-analysis of randomized controlled trials," *Physical Therapy*, vol. 98, no. 4, pp. 231–242, 2018.
- [11] D. A. Sutton, P. Côté, J. J. Wong et al., "Is multimodal care effective for the management of patients with whiplash-associated disorders or neck pain and associated disorders? A systematic review by the Ontario Protocol for Traffic Injury Management (OPTIMa) Collaboration," *The Spine Journal*, vol. 16, no. 12, pp. 1541–1565, 2016.
- [12] K. Fredin and H. Lorås, "Manual therapy, exercise therapy or combined treatment in the management of adult neck pain - a systematic review and meta-analysis," *Musculoskeletal Science* and Practice, vol. 31, pp. 62–71, 2017.
- [13] E. Gattie, J. A. Cleland, and S. Snodgrass, "The effectiveness of trigger point dry needling for musculoskeletal conditions by physical therapists: a systematic review and meta-analysis," *Journal of Orthopaedic & Sports Physical Therapy*, vol. 47, no. 3, pp. 133–149, 2017.
- [14] D. Moher, A. Liberati, J. Tetzlaff, D. G. Altman, and T. P. Group, "Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement," *PLoS Med*, vol. 6, Article ID e1000097, 2009.
- [15] J. P. T. Higgins, D. G. Altman, P. C. Gotzsche et al., "The Cochrane Collaboration's tool for assessing risk of bias in randomised trials," *BMJ*, vol. 343, Article ID d5928, 2011.
- [16] C. G. Maher, C. Sherrington, R. D. Herbert, A. M. Moseley, and M. Elkins, "Reliability of the PEDro scale for rating quality of randomized controlled trials," *Physical Therapy*, vol. 83, no. 8, pp. 713–721, 2003.
- [17] H. J. Schünemann, A. D. Oxman, J. Brozek et al., "GRADE: assessing the quality of evidence for diagnostic recommendations," *Evidence-Based Medicine*, vol. 13, no. 6, pp. 162-163, 2008.
- [18] T. M. Austin, R. R. Richter, and C. A. Sebelski, "Introduction to the GRADE approach for guideline development: considerations for physical therapist practice," *Physical Therapy*, vol. 94, no. 11, pp. 1652–1659, 2014.
- [19] X. Wan, W. Wang, J. Liu, and T. Tong, "Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range," BMC Med Res Methodol, vol. 14, pp. 1–13, 2014.
- [20] D. Luo, X. Wan, J. Liu, and T. Tong, "Optimally estimating the sample mean from the sample size, median, mid-range, and/ or mid-quartile range," *Statistical Methods in Medical Re*search, vol. 27, no. 6, pp. 1785–1805, 2018.
- [21] G. M. Sullivan and R. Feinn, "Using effect size-or why the P value is not enough," *Journal of Graduate Medical Education*, vol. 4, no. 3, pp. 279–282, 2012.
- [22] J. J. Deeks and J. P. T. A. D Higgins, "Chapter 9: analyzing data and undertaking metanalyses," in *Cochrane Handbook for Systematic Reviews of Interventions*, J. P. T. Higgins, R. Churchill, J. Chandl, and M. S. Cumpst, Eds., Cochrane,

- London, UK, 2017, http://www.training.cochrane.org/handbook.
- [23] J. L. Arias-Buría, M. M. Franco-Hidalgo-Chacón, J. A. Cleland, M. Palacios-Ceña, S. Fuensalida-Novo, and C. Fernández-de-las-Peñas, "Effects of kinesio taping on postneedling induced pain after dry needling of active trigger point in individuals with mechanical neck pain," *Journal of Manipulative and Physiological Therapeutics*, vol. 43, no. 1, pp. 32–42, 2020.
- [24] J. V. León-Hernández, A. Martín-Pintado-Zugasti, L. G. Frutos et al., "Immediate and short-term effects of the combination of dry needling and percutaneous TENS on postneedling soreness in patients with chronic myofascial neck pain," *Brazilian Journal of Physical Therapy*, vol. 20, no. 5, pp. 422–431, 2016.
- [25] P. Valiente-Castrillo, A. Martín-Pintado-Zugasti, C. Calvo-Lobo, H. Beltran-Alacreu, and J. Fernández-Carnero, "Effects of pain neuroscience education and dry needling for the management of patients with chronic myofascial neck pain: a randomized clinical trial," Acupuncture in Medicine, vol. 5, 2020.
- [26] E. A. Tough, A. R. White, S. H. Richards, and J. L. Campbell, "Myofascial trigger point needling for whiplash associated pain - a feasibility study," *Manual Therapy*, vol. 15, no. 6, pp. 529–535, 2010.
- [27] M. Sterling, B. Vicenzino, T. Souvlis, and L. B. Connelly, "Dry-needling and exercise for chronic whiplash-associated disorders," *Pain*, vol. 156, no. 4, pp. 635–643, 2015.
- [28] G. M. Gallego-Sendarrubias, D. Rodríguez-Sanz, C. Calvo-Lobo, and J. L. Martín, "Efficacy of dry needling as an adjunct to manual therapy for patients with chronic mechanical neck pain: a randomised clinical trial," *Acupuncture in Medicine*, vol. 38, 2020.
- [29] E. Cerezo-Téllez, M. Torres-Lacomba, I. Fuentes-Gallardo et al., "Effectiveness of dry needling for chronic nonspecific neck pain: a randomized, single-blinded," *Clinical Trial*, vol. 157, 2016.
- [30] E. Cerezo-Téllez, M. T. Lacomba, I. Fuentes-Gallardo, O. Mayoral del Moral, B. Rodrigo-Medina, and C. Gutiérrez Ortega, "Dry needling of the trapezius muscle in office workers with neck pain: a randomized clinical trial," *Journal* of Manual & Manipulative Therapy, vol. 24, no. 4, pp. 223– 232, 2016.
- [31] F. F. Stieven, G. E. Ferreira, M. Wiebusch, F. X. De Araújo, L. H. T. da Rosa, and M. F. Silva, "No added benefit of combining dry needling with guideline-based physical therapy when managing chronic neck pain: a randomized controlled trial," *The Journal of Orthopaedic & Sports Physical Therapy*, vol. 50, pp. 1–21, 2020.
- [32] J. A. Cleland, J. D. Childs, and J. M. Whitman, "Psychometric properties of the neck disability index and numeric pain rating scale in patients with mechanical neck pain," *Archives* of *Physical Medicine and Rehabilitation*, vol. 89, no. 1, pp. 69–74, 2008.
- [33] P. E. Bijur, C. T. Latimer, and E. J. Gallagher, "Validation of a verbally administered numerical rating scale of acute pain for use in the emergency department," *Academic Emergency Medicine*, vol. 10, no. 4, pp. 390–392, 2003.
- [34] C. Fernández-de-Las-Peñas and J. Nijs, "Trigger point dry needling for the treatment of myofascial pain syndrome: current perspectives within a pain neuroscience paradigm," *Journal of Pain Research*, vol. 12, pp. 1899–1911, 2019.
- [35] J. E. Bialosky, J. M. Beneciuk, M. D. Bishop et al., "Unraveling the mechanisms of manual therapy: modeling an approach,"

- The Journal of Orthopaedic & Sports Physical Therapy, vol. 48, pp. 1–31, 2017.
- [36] L. C. Carlesso, J. C. MacDermid, and L. P. Santaguida, "Standardization of adverse event terminology and reporting in orthopaedic physical therapy: application to the cervical spine," *Journal of Orthopaedic & Sports Physical Therapy*, vol. 40, no. 8, pp. 455–463, 2010.
- [37] S. Brady, J. McEvoy, J. Dommerholt, and C. Doody, "Adverse events following trigger point dry needling: a prospective survey of chartered physiotherapists," *Journal of Manual & Manipulative Therapy*, vol. 22, no. 3, pp. 134–140, 2014.
- [38] D. Boyce, H. Wempe, C. Campbell et al., "Adverse events associated with therapeutic dry needling," *International Journal of Sports Physical Therapy*, vol. 15, no. 1, pp. 103–113, 2020
- [39] M. Cummings, R. Ross-Marrs, and R. Gerwin, "Pneumothorax complication of deep dry needling demonstration," Acupuncture in Medicine, vol. 32, no. 6, pp. 517–519, 2014.
- [40] T. Uzar, I. Turkmen, E. B. Menekse, A. Dirican, P. Ekaterina, and S. Ozkaya, "A case with iatrogenic pneumothorax due to deep dry needling," *Radiology Case Reports*, vol. 13, no. 6, pp. 1246–1248, 2018.
- [41] C. J. Mansfield, L. Vanetten, R. Willy, S. di Stasi, R. Magnussen, and M. Briggs, "The effects of needling therapies on muscle force production: a systematic review and meta-analysis," *Journal of Orthopaedic & Sports Physical Therapy*, vol. 49, no. 3, pp. 154–170, 2019.